Objective: The anti-cyclic citrullinated peptide (anti-CCP) antibody has been increasingly used in the field of rheumatology, and various manufacturers have developed a variety of anti-CCP assays using mainly ELISA techniques. This study evaluated the performance of recently marketed automated chemiluminescence enzyme immunoassays for anti-CCP.
Methods: We investigated four anti-CCP assays (Diastat anti-CCP ELISA assay, Axsym anti-CCP assay on the Axsym system, the Architect anti-CCP assay on the Architect i2000 system and the Elecsys anti-CCP assay on the Cobas e 411 analyzer). Samples from 64 patients with RA and 152 controls, including patients with various autoimmune diseases, were studied. We assessed the clinical sensitivities and specificities, and compared the qualitative and quantitative results of each anti-CCP assay.
Results: Using the manufacturers' cut-off, diagnostic sensitivities ranged from 90.6 to 93.8% and the specificities ranged from 85.5 to 86.8%. The areas under the curve were comparable among the different assays, and qualitative agreements ranged from 97.2 to 99.1%. In the quantitative results, all anti-CCP assays were significantly correlated (P < 0.001), but the correlation coefficient ranged from 0.615 to 0.861. Especially, the correlation coefficients between the automated anti-CCP assays were higher than those between the ELISA assay (Diastat) and the automated assays.
Conclusions: The overall diagnostic performance of the automated anti-CCP assays was comparable, and it provides reliable information on antibody levels, making them useful in monitoring disease activity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/rheumatology/kep391 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identifying people at risk of rheumatoid arthritis in primary care: qualitative study.
Br J Gen Pract
January 2025
University of Leeds Faculty of Medicine and Health, Leeds Institute of Health Sciences, Leeds, United Kingdom
Background: Identification of rheumatoid arthritis (RA) in primary care is challenging and often delayed. Anti-cyclic citrullinated peptide (anti-CCP) antibody testing of people presenting to primary care with new-onset musculoskeletal symptoms without synovitis could help address this; those testing positive are at increased risk of developing RA.
Aim: To explore how primary care clinicians currently identify and refer patients with suspected RA, and the behaviours required to implement a prediction model for guiding targeted anti-CCP testing for non-specific musculoskeletal symptoms in primary care.
The role of Anti-PAD4, Anti-CarP, and Anti-RA33 antibodies combined with RF and ACPA in predicting abatacept response in rheumatoid arthritis.
Arthritis Res Ther
January 2025
Department of Medical Science and Public Health, Rheumatology Unit, University of Cagliari, Azienda Ospedaliero Universitaria di Cagliari, SS 554 Monserrato (CA), Bivio Sestu, Monserrato, 09042, Italy.
Objectives: To explore the role of newly emerging autoantibodies (AAbs) - peptidyl-arginine deiminase 4 (aPAD4), carbamylated proteins (aCarP), and anti-RA33 (aRA33) - alongside the traditionally assessed rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), in predicting the response to abatacept (ABT) and its retention rate in rheumatoid arthritis (RA) patients.
Methods: Data from 121 consecutive ABT-treated RA patients were recorded. The RF and ACPA status were retrospectively assessed by reviewing the patients' clinical records.
Diagnostic Value of Combined Test of Anti-Cyclic Citrullinated Peptide Antibody, AKA Antibody, Carp Antibody, and Rheumatoid Factor for Rheumatoid Arthritis.
Int J Rheum Dis
January 2025
Department of Rheumatism, The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, China.
Objective: To analyze the diagnostic value of a combined test of anti-cyclic citrullinated peptide antibody (CCP), anti-keratin antibody (AKA), anti-carbamylated protein antibody (Carp antibody), and rheumatoid factor (RF) in the early diagnosis of rheumatoid arthritis (RA).
Methods: Sixty cases of RA admitted to our hospital from 2021 to 2022 (observation group) were selected, along with 50 cases of healthy physical examiners (control group). The results of CCP antibody, AKA antibody, Carp antibody, and rheumatoid factor in both groups were analyzed: the concentration of CCP antibody, AKA antibody, Carp antibody, and rheumatoid factor in each group at different levels; the comparison of various testing methods with the "gold standard" test; and the ROC curve analysis of CCP antibody, AKA antibody, Carp antibody, and rheumatoid factor in each group.
A portable optical detection system for rapid quantification of two rheumatoid arthritis biomarkers.
Anal Chim Acta
January 2025
Department of Power Mechanical Engineering, National Tsing Hua University, Hsinchu, Taiwan; Institute of NanoEngineering and Microsystems, National Tsing Hua University, Hsinchu, Taiwan. Electronic address:
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes joint damage and progressive destruction of adjacent cartilage and bones. Quick and accurate detection of rheumatoid factors (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP) in serum is effective in diagnosing RA and preventing its progression. However, current methods for detecting these two biomarkers are costly, time-consuming, labor-intensive, and require specialized equipment.
View Article and Find Full Text PDFSynovial Fluid Markers and Extracellular Vesicles in Rheumatoid Arthritis.
Medicina (Kaunas)
November 2024
Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University in Bratislava, Sasinkova 4, 811 08 Bratislava, Slovakia.
In recent years, numerous potential prognostic biomarkers for rheumatoid arthritis (RA) have been investigated. Despite these advancements, clinical practice primarily relies on autoantibody tests-for rheumatoid factor (RF) and anti-citrullinated protein antibody (anti-CCP)-alongside inflammatory markers, such as the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Expanding the repertoire of diagnostic and therapeutic biomarkers is critical for improving clinical outcomes in RA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!